莱美药业：“尼可地尔片”等产品取得注册证

Company Overview - Recently, Laimei Pharmaceutical (SZ 300006, closing price: 4.58 yuan) announced the approval of two drug registration certificates by the National Medical Products Administration for Nicorandil tablets and Ketorolac Tromethamine injection [1] Financial Performance - For the year 2024, Laimei Pharmaceutical's revenue composition is as follows: 84.09% from pharmaceutical manufacturing, 13.06% from pharmaceutical distribution, 1.64% from other businesses, and 1.21% from service income [1] Market Position - As of the report, Laimei Pharmaceutical has a market capitalization of 4.8 billion yuan [1]